Ampio Pharmaceuticals, Inc. (AMPE) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2018

Ampio Pharmaceuticals, Inc.

CIK: 1411906 Ticker: AMPE
Document And Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2018
Mar. 01, 2019
Jun. 30, 2018
Document And Entity Information [Abstract]   
Document Type10-K  
Amendment Flagfalse  
Document Period End DateDec. 31, 2018  
Document Fiscal Year Focus2018  
Document Fiscal Period FocusFY  
Entity Voluntary FilersNo  
Entity Current Reporting StatusYes  
Entity Registrant NameAmpio Pharmaceuticals, Inc.  
Entity Central Index Key0001411906  
Current Fiscal Year End Date--12-31  
Entity Filer CategoryAccelerated Filer  
Trading SymbolAMPE  
Entity Common Stock, Shares Outstanding 111,127,878 
Entity Well-known Seasoned IssuerNo  
Entity Public Float  $ 174.5
Entity Emerging Growth Companyfalse  
Entity Small Businesstrue  
Entity Shell Companyfalse  

View differences made from one year to another to evaluate Ampio Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Ampio Pharmaceuticals, Inc..


Assess how Ampio Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Ampio Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools


Learn More
Bullish Bearish Neutral
Filter Sentiment:
Filter Category:
Filter Subcategory:
Inside Ampio Pharmaceuticals, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Balance Sheets
Balance Sheets (Parenthetical)
Statements Of Cash Flows
Statements Of Operations
Statements Of Stockholders' Equity (Deficit)
Statements Of Stockholders' Equity (Deficit) (Parenthetical)
Basis Of Presentation
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Additional Information (Detail)
Commitments And Contingencies - Rent Expense (Detail)
Commitments And Contingencies - Summary Of Commitments And Contingencies (Detail)
Common Stock
Common Stock (Capital Stock Narrative) (Details)
Common Stock (Common Stock Issued For Services) (Details)
Common Stock (Confidentially Marketed Public Offering Narrative) (Details)
Common Stock (Controlled Equity Offering) (Details)
Common Stock (Registered Direct Offering Narrative) (Details)
Common Stock (Shelf Registration Narrative) (Details)
Employee Benefit Plan
Equity Instruments
Equity Instruments (Tables)
Equity Instruments - Assumptions For Warrants Issued (Detail)
Equity Instruments - Assumptions Used In Computing Fair Value Of All Options Granted (Detail)
Equity Instruments - Options, Additional Information (Detail)
Equity Instruments - Stock Option Activity (Detail)
Equity Instruments - Summary Of Stock Options Outstanding And Exercisable (Detail)
Equity Instruments - Summary Of Stock-Based Compensation Expense (Detail)
Equity Instruments - Warrants Issued In Conjunction With Its Senior Convertible Debentures (Detail)
Equity Instruments - Warrants, Additional Information (Detail)
Fair Value Considerations
Fair Value Considerations (Tables)
Fair Value Considerations - Financial Assets And Liabilities (Detail)
Fair Value Considerations - Sets Forth A Reconciliation Of Changes (Detail)
Going Concern
Going Concern - Additional Information (Detail)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Detail)
Income Taxes - Deferred Tax Assets And Liabilities (Detail)
Income Taxes - Reconciliation Of Effective Tax Rate (Detail)
Related Party Transactions
Related Party Transactions - Additional Information (Detail)
Subsequent Events
Subsequent Events - Additional Information (Detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Summary Of Significant Accounting Policies - Depreciation Expenses (Detail)
Summary Of Significant Accounting Policies - Potentially Dilutive Securities, Excluded (Detail)
Summary Of Significant Accounting Policies - Schedule Of Fixed Assets (Detail)
Ticker: AMPE
CIK: 1411906
Form Type: 10-K Annual Report
Accession Number: 0001558370-19-002244
Submitted to the SEC: Mon Mar 18 2019 12:42:50 PM EST
Accepted by the SEC: Mon Mar 18 2019
Period: Monday, December 31, 2018
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: